Virafin for moderate Covid 19

April 26, 2021

The Drugs Controller General of India (DGCI) on Friday approved the emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b ‘Virafin’ for treating moderate COVID-19 infection for adults. Zydus Cadila announced that it has received emergency use approval from DCGI to use Virafin for the treatment of moderate COVID-19 infections. As per the report, a single-dose subcutaneous regimen of the drug will make the treatment of COVID-19 more convenient. The company had said that if administered early on during COVID-19, Virafin may help patients recover faster and avoid much of the complications. It will be available on the prescription of a medical specialist.

Virafin for moderate Covid 19

RELATED NEWS

Cardinal calls for further probe into X-Press Pearl environmental damage

Reservoir levels fall sharply in eastern Sri Lanka

Government launches Rs. 2.5 billion revenue-generating development programme

EU helps Lanka build eco-label system

Nepal’s Prime Minister walks the tightrope between India and China

That Saffron Letter

Cardinal calls for further probe into X-Press Pearl environmental damage

Reservoir levels fall sharply in eastern Sri Lanka

Government launches Rs. 2.5 billion revenue-generating development programme

Police arrest over 1,000 foreigners over cybercrime, financial fraud in 2026

Interpol hunts 93 Lankan suspects hiding overseas

Suicides rise sharply in Northern Province

Summit to map post-crisis growth